Collegium Pharmaceutical, Inc. Revenue
Collegium Pharmaceutical, Inc. (COLL) reported Revenue of $199.88 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $199.88M, a 6.32% increase year-over-year.
- Collegium Pharmaceutical, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $193.52M, a 8.87% increase year-over-year.
- Collegium Pharmaceutical, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $205.45M, a 12.92% increase year-over-year.
- Collegium Pharmaceutical, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $209.36M, a 31.42% increase year-over-year.
- Collegium Pharmaceutical, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $780.57M, a 23.62% increase from fiscal 2024.
- Collegium Pharmaceutical, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $631.45M, a 11.41% increase from fiscal 2023.
- Collegium Pharmaceutical, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $566.77M, a 22.17% increase from fiscal 2022.
- Collegium Pharmaceutical, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $463.93M, a 67.56% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $199.88M 10-Q · filed 2026-08-06 | $393.40M 10-Q · filed 2026-08-06 | $598.85M derived: sum of 3 quarters · filed 2026-08-06 | $808.21M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $193.52M 10-Q · filed 2026-05-07 | $398.97M derived: sum of 2 quarters · filed 2026-05-07 | $608.33M derived: sum of 3 quarters · filed 2026-05-07 | $796.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $205.45M 10-K · filed 2026-02-26 | $414.81M derived: sum of 2 quarters · filed 2026-02-26 | $602.81M derived: sum of 3 quarters · filed 2026-08-06 | $780.57M 10-K · filed 2026-02-26 |
| 2025-09-30 | $209.36M 10-K · filed 2026-02-26 | $397.36M derived: sum of 2 quarters · filed 2026-08-06 | $575.12M 10-Q · filed 2025-11-06 | $757.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $188.00M 10-Q · filed 2026-08-06 | $365.76M 10-Q · filed 2026-08-06 | $547.71M derived: sum of 3 quarters · filed 2026-08-06 | $707.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $177.76M 10-Q · filed 2026-05-07 | $359.71M derived: sum of 2 quarters · filed 2026-05-07 | $519.01M derived: sum of 3 quarters · filed 2026-05-07 | $664.28M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $181.95M 10-K · filed 2026-02-26 | $341.25M derived: sum of 2 quarters · filed 2026-02-26 | $486.53M derived: sum of 3 quarters · filed 2026-02-26 | $631.45M 10-K · filed 2026-02-26 |
| 2024-09-30 | $159.30M 10-K · filed 2026-02-26 | $304.58M derived: sum of 2 quarters · filed 2026-02-26 | $449.50M 10-Q · filed 2025-11-06 | $599.25M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $145.28M 10-K · filed 2026-02-26 | $290.20M 10-Q · filed 2025-08-07 | $439.94M derived: sum of 3 quarters · filed 2026-02-26 | $576.65M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $144.92M 10-K · filed 2026-02-26 | $294.67M derived: sum of 2 quarters · filed 2026-02-26 | $431.38M derived: sum of 3 quarters · filed 2026-02-26 | $566.92M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $149.75M 10-K · filed 2025-02-27 | $286.45M derived: sum of 2 quarters · filed 2025-02-27 | $422.00M derived: sum of 3 quarters · filed 2025-02-27 | $566.77M 10-K · filed 2026-02-26 |
| 2023-09-30 | $136.71M 10-K · filed 2025-02-27 | $272.25M derived: sum of 2 quarters · filed 2025-02-27 | $417.02M 10-Q · filed 2024-11-07 | $546.64M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $135.55M 10-K · filed 2025-02-27 | $280.31M 10-Q · filed 2024-08-08 | $409.93M derived: sum of 3 quarters · filed 2025-02-27 | $536.95M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $144.77M 10-K · filed 2025-02-27 | $274.39M derived: sum of 2 quarters · filed 2025-02-27 | $401.40M derived: sum of 3 quarters · filed 2025-02-27 | $524.95M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $129.62M 10-K · filed 2024-02-22 | $256.63M derived: sum of 2 quarters · filed 2024-02-22 | $380.18M derived: sum of 3 quarters · filed 2024-02-22 | $463.93M 10-K · filed 2025-02-27 |
| 2022-09-30 | $127.01M 10-K · filed 2024-02-22 | $250.56M derived: sum of 2 quarters · filed 2024-02-22 | $334.31M 10-Q · filed 2023-11-07 | $361.68M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $123.55M 10-K · filed 2024-02-22 | $207.30M 10-Q · filed 2023-08-03 | $234.66M derived: sum of 3 quarters · filed 2024-02-22 | $313.50M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $83.75M 10-K · filed 2024-02-22 | $111.11M derived: sum of 2 quarters · filed 2024-02-22 | $189.96M derived: sum of 3 quarters · filed 2024-02-22 | $272.90M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $27.36M 10-K · filed 2023-02-23 | $106.20M derived: sum of 2 quarters · filed 2023-02-23 | $189.15M derived: sum of 3 quarters · filed 2023-02-23 | $276.87M 10-K · filed 2024-02-22 |
| 2021-09-30 | $78.84M 10-K · filed 2023-02-23 | $161.78M derived: sum of 2 quarters · filed 2023-02-23 | $249.51M 10-Q · filed 2022-11-03 | $325.78M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $82.94M 10-K · filed 2023-02-23 | $170.66M 10-Q · filed 2022-08-04 | $246.93M derived: sum of 3 quarters · filed 2023-02-23 | $326.11M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $87.72M 10-K · filed 2023-02-23 | $163.99M derived: sum of 2 quarters · filed 2023-02-23 | $243.17M derived: sum of 3 quarters · filed 2023-02-23 | $321.23M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $76.27M 10-K · filed 2022-02-24 | $155.45M derived: sum of 2 quarters · filed 2022-02-24 | $233.50M derived: sum of 3 quarters · filed 2022-02-24 | $310.02M 10-K · filed 2023-02-23 |
| 2020-09-30 | $79.18M 10-K · filed 2022-02-24 | $157.23M derived: sum of 2 quarters · filed 2022-02-24 | $233.75M 10-Q · filed 2021-11-04 | $307.95M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $78.06M 10-K · filed 2022-02-24 | $154.57M 10-Q · filed 2021-08-05 | $228.77M derived: sum of 3 quarters · filed 2022-02-24 | $301.71M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $76.51M 10-K · filed 2022-02-24 | $150.71M derived: sum of 2 quarters · filed 2022-02-24 | $223.66M derived: sum of 3 quarters · filed 2022-02-24 | $298.70M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $74.20M 10-K · filed 2021-02-25 | $147.15M derived: sum of 2 quarters · filed 2021-02-25 | $222.19M derived: sum of 3 quarters · filed 2021-02-25 | $296.70M 10-K · filed 2022-02-24 |
| 2019-09-30 | $72.94M 10-K · filed 2021-02-25 | $147.98M derived: sum of 2 quarters · filed 2021-02-25 | $222.50M 10-Q · filed 2020-11-05 | $295.93M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $75.04M 10-K · filed 2021-02-25 | $149.56M 10-Q · filed 2020-08-05 | $222.98M derived: sum of 3 quarters · filed 2021-02-25 | $293.16M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $74.52M 10-K · filed 2021-02-25 | $147.94M derived: sum of 2 quarters · filed 2021-02-25 | $218.12M derived: sum of 3 quarters · filed 2021-02-25 | $291.18M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $73.43M 10-K · filed 2020-02-27 | $143.60M derived: sum of 2 quarters · filed 2020-02-27 | $216.66M derived: sum of 3 quarters · filed 2020-02-27 | $280.41M 10-K · filed 2021-02-25 |
| 2018-09-30 | $70.18M 10-K · filed 2020-02-27 | $143.24M derived: sum of 2 quarters · filed 2020-02-27 | $206.99M 10-Q · filed 2019-11-06 | $217.78M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $73.06M 10-K · filed 2020-02-27 | $136.81M 10-Q · filed 2019-08-07 | $147.60M derived: sum of 3 quarters · filed 2020-02-27 | $159.55M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $63.75M 10-K · filed 2020-02-27 | $74.54M derived: sum of 2 quarters · filed 2020-02-27 | $86.49M derived: sum of 3 quarters · filed 2020-02-27 | $90.05M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $10.79M 10-K · filed 2019-02-27 | $22.74M derived: sum of 2 quarters · filed 2019-02-27 | $26.30M derived: sum of 3 quarters · filed 2019-02-27 | $28.48M 10-K · filed 2020-02-27 |
| 2017-09-30 | $11.95M 10-K · filed 2019-02-27 | $15.51M derived: sum of 2 quarters · filed 2019-02-27 | $17.68M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $3.56M 10-K · filed 2019-02-27 | $5.73M 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | $2.17M 10-K · filed 2019-02-27 | |||
| 2016-12-31 | $1.71M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |